The company stated that Canada’s patent office has issued a notice of allowance (NOA) for a patent relating to methods to treat ALS using the therapy.
The patent offers protection until 2037 and completes the intellectual property (IP) coverage for ALS across all important geographic areas where the therapy can be marketed, including the US, South Africa, and Eurasia.
AB Science said that masitinib is also eligible for regulatory data protection in the country.
This helps to prevent generic competition for eight years after initial approval.
Earlier this year, Japan’s patent office also issued an NOA for masitinib for the same condition.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
Under the notice of compliance with conditions (NOC/c) policy, AB Science received authorisation from Health Canada to file a new drug submission for masitinib to treat ALS.
The US Food and Drug Administration and the European Medicines Agency granted orphan drug designation to masitinib.
According to AB Science, approximately 3,000 Canadians are now living with ALS.
In 2021, the company signed an exclusive licensing agreement with the University of Chicago to carry out research on Covid-19 prevention and treatment with masitinib and other drugs.